SciELO - Scientific Electronic Library Online

 
vol.43 issue1Internal jugular vein cannulation: How much safety can we offer?Liquid handling, lidocaine and epinephrine in liposuction. The properly form author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Anestesiología

Print version ISSN 0120-3347

Abstract

CRISTANCHO, Rafael Alfonso; VECINO, Andres I  and  MISAS, Juan Diego. Cost/effectiveness evaluation of three fixed combinations of acetaminophen and opioids in the management of acute pain in Colombia. Rev. colomb. anestesiol. [online]. 2015, vol.43, n.1, pp.87-94. ISSN 0120-3347.

Objective: To compare the cost-effectiveness of three different formulations indicated for moderate and severe acute pain, commercialized in Colombia [acetaminophen 500 mg + codeine 30 mg (AC), acetaminophen 500 mg + hydrocodone 5 mg (AH) and acetaminophen 325 mg+ tramadol 37.5 mg (AT)]. Materials and methods:Cost-effectiveness analysis using the NNT as the health outcome indicator. The costs were evaluated in two specific settings: Institutional Channel (IC), representing the cost for the Colombian Ministry of Health (SISMED 2011); Retail Channel (RC), representing consumer prices, obtained from the IMS annual average for 2011, plus an adjustment to include the average profit margin for pharmacies (10%). The incremental cost effectiveness ratios (ICER) were calculated for the three formulations and the two settings (IC and RC). The intervention values are expressed in Colombian pesos (COP). Results: The prices/NNT for each formulation were $1816 COP/2.2 for AC, $4772 COP/2.3 for AH and $5342/2.6 for AT. Using these data and taking AC as the comparator, the ICER for the other formulations shows the following results: in the RC, $5065 COP for AT and $19,600 COP for AH; in the IC setting, $8790 COP for AT and $29,460 COP for AH. The probabilistic sensitivity analysis demonstrated that the majority of simulation results fell between the 1st and 4th quadrants of the cost-effectiveness matrix, using AC as a reference. Conclusion: The analysis, from the payer and patient perspectives, demonstrates that the AC formulation has a lower cost and is more effective inreducingpain within the first 4-6 h after administration, compared with the AH and AT formulations in their specific indications.

Keywords : Economics; Pharmaceutical; Analgesics; Opioid; Acute Pain; Public Health; Colombia.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )